Protaxos® (strontium ranelate): New restricted indication and contraindications for use

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive

Date: 13 August 2014

Description: This issue was highlighted in a previous NPCB Safety Alert issued on 27 January 2014. Following completion of NPCB’s benefit-risk profile review related to cardiovascular risk, the indications of Protaxos® have been tightened, and it is contraindicated in patients with established, current or past history of ischaemic heart disease, peripheral artery disease, or those with uncontrolled hypertension. Prescribers are advised to assess and monitor patient’s cardiovascular risk before and during treatment. A Direct Healthcare Professional Communication (DHPC) regarding this issue, along with a Prescriber Checklist, has been approved by NPCB and released by Servier Malaysia Sdn. Bhd.

Comments (0)

There are no comments posted here yet

Leave your comments

Posting comment as a guest.
0 Characters
Attachments (0 / 3)
Share Your Location

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA

Main Menu English

Choose Your Language